Physiological mediators in nonsteroidal anti-inflammatory drugs (NSAIDs)-induced impairment of gastric mucosal defense and adaptation. Focus on nitric oxide and lipoxins

Journal of Physiology and Pharmacology

Volumn 59, Issue SUPPL.2, 2008, Pages 89-102

  Brzozowski, Tomasz ^a   Konturek, P C ^b   Pajdo, R ^a   Ptak Belowska, A ^a   Kwiecien, S ^a   Pawlik, M ^a   Drozdowicz, D ^a   Sliwowski, Z ^a   Brzozowski, B ^a   Konturek, S J ^a   Pawlik, W W ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Aspirin triggered lipoxin; Cyclooxygenase; Gastric adaptation; Nitric oxide; Nitric oxide releasing aspirin; Nonsteroidal anti inflammatory drugs; Prostaglandins

Indexed keywords

5 HYDROXYICOSATETRAENOIC ACID; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; LEUKOTRIENE C4; LEUKOTRIENE D4; LIPOXIN; LIPOXIN A; LIPOXIN B; N ACETYL S NITROSOPENICILLAMINE; NAPROXEN; NITRIC OXIDE; NITRONAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; ROFECOXIB;

ADAPTATION; ANTIOXIDANT ACTIVITY; CONFERENCE PAPER; DIGESTIVE SYSTEM ULCER; DRUG MEGADOSE; ENZYME INHIBITION; HEART PROTECTION; HELICOBACTER INFECTION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROSTAGLANDIN SYNTHESIS INHIBITION; STOMACH MUCOSA INJURY; STOMACH PROTECTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; GASTRIC MUCOSA; HUMANS; LIPOXINS; NITRIC OXIDE; NITRIC OXIDE DONORS;

EID: 51449109599     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. Douthwaite AH, Lintott SAM. Gastroscopic observation of the effect of aspirin and certain other substances on the stomach. Lancet 1938; 2: 1222-1225.
2. McCarthy DM. Nonsteroidal anti-inflammatory drugs - the clinical dilemmas. Scand J Gastroenterol 1992; 27 (suppl.): 9-16.
3. Talley NJ. Chronic peptic ulceration and nonsteroidal anti-inflammatory drugs: More to be done about NSAIDs? Gastroenterology 1992; 102: 1074-1078.
4. Hawkey CJ. Gastroduodenal problems associated with nonsteroidal anti-inflammatory drugs. Scand J Gastroenterol 1993; 28 (suppl.) 200: 94-95.
5. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112: 1000-1016.
6. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971; 231: 232-235.
7. Wallace JL. Recent advances in gastric ulcer therapeutics. Curr Opin Pharmacol 2005; 5: 573-577.
8. Konturek SJ, Piastucki I, Brzozowski T, et al. Role of prostaglandins in the formation of aspirin-induced gastric ulcers. Gastroenterology 1981; 80: 4-9.
9. Pihan G, Rogers C, Szabo S. Vascular injury in acute gastric mucosal damage; mediatory role of leukotrienes. Dig Dis Sci 1998; 33: 625-632.
10. Konturek SJ, Brzozowski T, Drozdowicz D, Beck G. Role of leukotrienes in acute gastric lesions induced by ethanol, taurocholate, aspirin, platelet activating factor and stress in rats. Dig Dis Sci 1988; 33: 806-813.
11. Asako H, Kubes P, Wallace JL, Woy RE, Granger DN. Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate. Gastroenterology 1992; 103: 146-152.
12. Andrews FJ, Malcontenti-Wilson C, O'Brien P.E. Expression of adhesion molecules and leukocyte recruitment into gastric mucosa following ischemia-reperfusion. Dig Dis Sci 1997; 42: 326-329.
13. Santucci L, Fiorucci S, Giansaqnti M, et al. Pentoxyfilline prevents indomethacin-induced acute gastric mucosal damage in rats: role of tumor necrosis factor alpha. Gut 1994; 35: 909-915.
14. Appleyard CB, McCafferty DM, Tigley AW, Swain MG, Wallace JL. Tumor necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. Am J Physiol 1996; 270: G-42-G48.
15. Vane JR, Bakhle S, Botting RM. Cyclooxygenase 1 and 2. Ann Rev Pharmacol Toxicology 1998: 38: 97-120.
16. Coruzzi G, Venturi N, Spaggiari S. Gastrointestinal safety of novel nonsteroidal anti-inflammatory drugs: selective COX-2 inhibitors and beyond. Acta Biomed 2007: 78: 96-110.
17. Brzozowski T, Konturek PC, Konturek SJ. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Microsc Res Technique 2001; 53: 343-353.
18. Jackson LM, Wu KC, Mahida YR, Jenkins D, Hawkey CJ. Cyclooxygenase (COX) 1 and 2 in normal, inflamed and ulcerated human gastric mucosa. Gut 2000; 47: 762-770.
19. Langenbach R, Morhan SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83: 483-492.
20. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for the inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000; 119: 706-714.
21. Brzozowski T, Konturek PC, Konturek SJ, et al. Role of prostaglandins generated by cyclooxygenase-1 and cyclooxygenase-2 in healing of ischemia-reperfusion-induced gastric lesions. Eur J Pharmacol 1999; 385: 47-61.
22. Davis NM, Sharkey KA, Asfaha S, et al. Aspirin causes rapid up-regulation of cyclooxygenase-2 expression in the stomach of rats. Aliment Pharmacol Ther 1997; 11: 1101-1108.
23. Schmassman A, Peskar B, Stettler C, et al. Effect of inhibition of prostaglandin endoperoxide synthase 2 in chronic gastrointestinal ulcer models in rats. Br J Pharmacol 1998; 123: 795-804.
24. Wallace JL. COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation. Sci World Journal 2006; 6: 577-588.
25. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N England J Med 2000; 343: 1520-1529.
26. Fiorucci S, Santucci L, Distrutti E. NSAID, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon. Dig Liv Dis 2007; 39: 1043-1051.
27. Brzozowski T. Experimental production of peptic ulcer, gastric damage and cancer models and their use in pathophysiological studies and pharmacological treatment - Polish achievements. J Physiol Pharmacol 2003; 54 (suppl. 3): 99-126.
28. Whittle BJR, Lopez-Belmonte J, Moncada S. Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat. Br J Pharmacol 1990; 99: 607-611.
29. Fiorucci S, Del Soldato P. NO-aspirin: mechanism of action and gastrointestinal safety. Dig Liv Dis 2003; 35 (suppl 2): S9-S19.
30. Fiorucci S, Distrutti E, Menezes de Lima O, et al. Relative contribution of acetylated cyclooxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J 2003; 17: 1171-1173.
31. Wallace JL. Nitric oxide, aspirin-triggered lipoxins and NO-aspirin in gastric protection. Inflamm Allergy Drug Targets 2006; 5: 133-137.
32. Brzozowska I, Targosz A, Sliwowski Z, et al. Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor. J Physiol Pharmacol 2004; 55: 773-790.
33. Brzozowski T, Konturek PC, Konturek SJ, et al. Gastroprotective and ulcer healing effects of nitric oxide-releasing nonsteroidal anti-inflammatory drugs. Dig Liv Dis 2000; 3: 583-594.
34. Fiorucci S, Di Lorenzo A, Renga B, Farneti S, Morelli A, Cirino G. Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2- naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection. J Pharmacol Exp Ther. 2004; 311: 1264-1271.
35. Wallace JL, de Lima OM, Fiorucci S. Lipoxins in gastric mucosal health and disease. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 251-255.
36. Konturek SJ, Konturek PC, Brzozowski T. Prostaglandins and ulcer healing. J Physiol Pharmacol 2005; 56 (Suppl 5): 5-31.
37. Fiorucci S, Antonelli E, Santucci L, et al. Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like proteases in rats. Gastroenterology 1999; 116: 1089-1106.
38. Eastwood GL, Quimby F. Effect of chronic aspirin ingestion on epithelial proliferation in rat gastric body, antrum and duodenum. Gastroenterology 1982; 82: 852-856.
39. Olivero JJ, Graham DY. Gastric adaptation to nonsteroidal anti-inflammatory drugs in man. Scand J Gastroenterol 1992; 27 (suppl.) 193: 53-58.
40. Konturek SJ, Dembinski A, Stoll R, Domschke W, Konturek SJ. Mucosal adaptation to aspirin induced gastric damage in humans. Studies on blood flow, gastric mucosal growth and neutrophil activation. Gut 1994; 35: 1197-1204.
41. Alderman BM, Cook GA, Familiary M, Yeomans ND, Giraud AS. Resistance to apoptosis is a mechanism of adaptation of rat stomach to aspirin. Am J Physiol 2000; 278: G839-G846.
42. Brzozowski T, Konturek PC, Konturek SJ, et al. Gastric adaptation to injury by repeated doses of aspirin strengthens mucosal defense against subsequent exposure to various strong irritants in rats. Gut 1995; 37: 749-757.
43. Brzozowski T, Konturek PC, Konturek SJ, Brzozowska I, Pawlik T. Role of prostaglandins in gastroprotection and adaptation. J Physiol Pharmacol 2005; 56(Suppl. 5): 75-88.
44. Wallace JL, McKnight GW, Bell CJ. Adaptation of rat gastric mucosa to aspirin requires mucosal contact. Am J Physiol 1995; 268: G134-G138.
45. Serhan CN. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? Prostaglandins 1997; 53: 107-137.
46. Chiang N, Fierro IM, Gronert K, Serhan CN. Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J Exp Med 2000; 191: 1197-1208.
47. von der Weid PY, Hollenberg MD, Fiorucci S, Wallace JL. Aspirin-triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone. Circulation 2004; 110: 1320-1325.
48. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivity for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci 1999; 96: 7563-7568.
49. Serhan CN, Maddox JF, Petasis NA, et al. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 1995; 34: 14609-14615.
50. 4 analog blocks phosphorylation of leukocyte-specific protein 1 in human neutrophils. J Immunol 2004; 173: 2091-2098.
51. KY J, Hu FL. Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases. World J Gastroenterol 2006; 12: 3789-3792.
52. Wilcox CM. Relationship between nonsteroidal anti-inflammatory drug use, Helicobacter pylori, and gastroduodenal mucosal injury. Gastroenterology 1997; 113(6 Suppl): 85-89.
53. Hawkey CJ, Tullassay Z, Szczepanski L, et al. Randomized controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter eradication for lesion prevention. Lancet 1998; 352: 1016-1021.
54. Brzozowski T, Konturek PC, Sliwowski Z, et al. Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals. J Physiol Pharmacol 2006; 57 (suppl. 3): 67-79.
55. Konturek JW, Dembinski A, Konturek SJ, Stachura J, Domschke W. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans. Gastroenterology 1998; 114: 245-255.
56. Souza MH, de Lima OM, Zamuner SR, Fiorucci S, Wallace JL. Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis. Am J Physiol Gastrointestinal Liver Physiol. 2003; 285: 54-61.
57. Fiorucci S, Santucci L, Wallace JL, et al. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci USA 2003; 100: 10937-10941.